Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5.

• DOI: 10.1200/jco.2017.35.5_suppl.20
• Publication Date: 2017-03-21T18:55:08Z
• Authors: Ilya Tsimafeyeu; Tatiana Zolotareva; Sergey Varlamov; Ruslan Zukov; Liubov Yu Vladimi...; Vladislav Petkau; Mikhail Mazhbich; Galina Statsenko; Sufia Safina; Igor Zaitsev; Dina Sakaeva; Alexander Popov; Pavel Borisov
• Keywords: Demographics; Systemic therapy

20 Background: The results of the 5-year overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) has been reported rarely. aim RENSUR5 registry study was to obtain real-world data on use therapies mRCC and assess OS Russian population. Methods: Patients were retrospectively identified at 11 cancer centers different regions Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St.Petersburg, Ufa). included if diagnosed from January 2010 2011. Anonymised collected through an online covering demographics, treatments outcomes. Results: 439 adult for analysis. Mean age diagnosis 60.9 (33-90) years (with 9% aged 3 75 years). predominantly male (70.2%), 67.7% had nephrectomy; clear-cell non-clear tumors detected 61.1% 7.7% patients, respectively. 271 (62%) received systemic therapy. Median duration therapy months (95% CI 9.5-12.5). majority treatment interferon only (n=145). 105 (23.9%) treated targeted 69 (15.7%) 2 lines. Survival outcomes are listed Table. Conclusions: is a large 'real-world' database assessing patterns Russia. Based this study, we assume that poor should be improved novel therapies. [Table: see text]